{"id":"bivalent-vaccines","safety":{"commonSideEffects":[{"rate":"10–30%","effect":"Injection site pain or swelling"},{"rate":"5–15%","effect":"Fatigue"},{"rate":"5–15%","effect":"Headache"},{"rate":"5–15%","effect":"Myalgia"},{"rate":"1–5%","effect":"Low-grade fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bivalent vaccines are formulated to contain antigens from two different pathogens or two variants of the same pathogen, enabling the immune system to generate protective antibodies and cellular responses against both targets in a single vaccination. This approach is commonly used for influenza (seasonal strains) and COVID-19 (original strain plus variant) vaccines to broaden immunological coverage.","oneSentence":"Bivalent vaccines stimulate immune responses against two distinct pathogenic targets or variants simultaneously.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:28:40.602Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Influenza prevention (bivalent formulations)"},{"name":"COVID-19 prevention (bivalent formulations against original and variant strains)"}]},"trialDetails":[{"nctId":"NCT05237947","phase":"PHASE4","title":"Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-01","conditions":"Human Papillomavirus-Related Cervical Carcinoma","enrollment":5000},{"nctId":"NCT06866405","phase":"PHASE3","title":"A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-04-16","conditions":"RSV Infection","enrollment":550},{"nctId":"NCT04936529","phase":"PHASE2","title":"A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-08-02","conditions":"Neuroblastoma","enrollment":286},{"nctId":"NCT06057948","phase":"PHASE2","title":"A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-09-21","conditions":"Neuroblastoma, High-risk Neuroblastoma, Metastatic Neuroblastoma","enrollment":94},{"nctId":"NCT07445763","phase":"","title":"TARSILA Real-World Evidence Study","status":"NOT_YET_RECRUITING","sponsor":"Inova Medical","startDate":"2026-04-30","conditions":"Respiratory Syncytial Virus (RSV), Maternal Immunization, Acute Respiratory Illness (ARI)","enrollment":5000},{"nctId":"NCT07377656","phase":"PHASE2","title":"Strengthening HPV Immunization Through EPI Leveraged Delivery","status":"NOT_YET_RECRUITING","sponsor":"International Vaccine Institute","startDate":"2026-01-16","conditions":"HPV Vaccine","enrollment":115},{"nctId":"NCT05951920","phase":"NA","title":"Lymph Node Aspiration to Decipher the Immune Response of Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine.","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-07-05","conditions":"COVID-19","enrollment":12},{"nctId":"NCT03309033","phase":"","title":"Extended Follow-up of Women Who Received One, Two, and Three Doses of the HPV Vaccine in the Costa Rica Vaccine Trial (CVT), ESCUDDO-CVT Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-07-02","conditions":"Human Papillomavirus Infection, Human Papillomavirus-Related Malignant Neoplasm","enrollment":991},{"nctId":"NCT05794230","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-03-27","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1528},{"nctId":"NCT06063057","phase":"PHASE1, PHASE2","title":"Inactivated Bivalent Enterovirus Vaccine (Vero Cell) Phase I/II Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2023-09-20","conditions":"Hand, Foot and Mouth Disease, Herpangina","enrollment":744},{"nctId":"NCT05916326","phase":"PHASE3","title":"Phase III Clinical Trial to Evaluate the Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula Polymorpha)","status":"COMPLETED","sponsor":"National Vaccine and Serum Institute, China","startDate":"2023-06-30","conditions":"Norovirus Infections, Norwalk Gastroenteritis","enrollment":8000},{"nctId":"NCT05541861","phase":"PHASE1","title":"Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2022-11-08","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":383},{"nctId":"NCT07326878","phase":"PHASE1","title":"Phase I Clinical Trial of Enterovirus Type71 - Coxsackievirus Type A16 Bivalent Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2025-12-30","conditions":"Hand, Foot and Mouth Disease (HFMD), HFMD, Hand, Foot and Mouth Disease","enrollment":144},{"nctId":"NCT05658523","phase":"PHASE3","title":"COVID-19 Booster Study in Healthy Adults in Australia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Murdoch Childrens Research Institute","startDate":"2023-02-28","conditions":"COVID-19","enrollment":496},{"nctId":"NCT07295028","phase":"PHASE1","title":"Study of an RSV-hMPV-PIV3 Trivalent Vaccine Candidate VXB-251 in Older Adults","status":"RECRUITING","sponsor":"Vicebio Australia Proprietary Limited","startDate":"2025-11-17","conditions":"Lower Respiratory Tract Disease, Healthy Participants","enrollment":240},{"nctId":"NCT07281677","phase":"PHASE4","title":"Immunogenicity and Safety of Sequential 2vHPV-9vHPV Vaccination in Girls Aged 9-14 Years","status":"RECRUITING","sponsor":"Zhejiang Provincial Center for Disease Control and Prevention","startDate":"2025-12-20","conditions":"HPV Infection","enrollment":400},{"nctId":"NCT05903183","phase":"PHASE2","title":"A Study to Evaluate the Safety and Immunogenicity of IVX-A12 in Participants of 60 to 85 Years of Age","status":"COMPLETED","sponsor":"Icosavax, Inc.","startDate":"2023-05-15","conditions":"Healthy","enrollment":264},{"nctId":"NCT06831786","phase":"EARLY_PHASE1","title":"Immunogenicity of COVID-19 Vaccine Co-administration With Influenza Vaccine in Healthy Volunteers","status":"COMPLETED","sponsor":"Prince of Songkla University","startDate":"2024-03-01","conditions":"COVID - 19","enrollment":36},{"nctId":"NCT05543993","phase":"","title":"COVID Booster in Pregnancy and Lactation","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2022-09-29","conditions":"COVID-19","enrollment":150},{"nctId":"NCT07254728","phase":"PHASE1","title":"A Study to Evaluate Vaxart's Oral Bivalent GI.1/GII.4 Norovirus Vaccine in Healthy Lactating Females and Their Nursing Infants","status":"COMPLETED","sponsor":"Vaxart","startDate":"2023-10-27","conditions":"Norovirus Infections","enrollment":76},{"nctId":"NCT05584202","phase":"PHASE2","title":"Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants","status":"TERMINATED","sponsor":"ModernaTX, Inc.","startDate":"2022-09-30","conditions":"SARS-CoV-2","enrollment":68},{"nctId":"NCT05168813","phase":"PHASE2, PHASE3","title":"Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern","status":"COMPLETED","sponsor":"COVID-19 Prevention Network","startDate":"2021-12-01","conditions":"SARS-CoV-2 Infection, HIV Infections, COVID-19","enrollment":14237},{"nctId":"NCT06684743","phase":"PHASE4","title":"Vaccine Effectiveness of a Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing RSV Hospitalizations in Adults","status":"RECRUITING","sponsor":"Tor Biering-Sørensen","startDate":"2024-11-18","conditions":"RSV","enrollment":690000},{"nctId":"NCT04537156","phase":"PHASE3","title":"Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xiamen University","startDate":"2020-09-05","conditions":"Cervical Intraepithelial Neoplasia, Cervical Cancer, Condylomata Acuminata","enrollment":9327},{"nctId":"NCT05032976","phase":"","title":"Korea Comirnaty Post-marketing Surveillance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2022-03-18","conditions":"COVID-19, Vaccines, Adverse Effects","enrollment":12000},{"nctId":"NCT07122661","phase":"","title":"STudy of Real World vaccinE Effectiveness of maTernal RSVpreF vaccinatiON Against Respiratory Syncytial Virus (RSV) in Hospitalised Infants in Australia (STREETON)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2025-08-11","conditions":"Respiratory Syncytial Virus (RSV), Respiratory Syncytial Virus, Lower Respiratory Tract Disease","enrollment":1},{"nctId":"NCT07232706","phase":"PHASE3","title":"Prevention of RSV Infection in Infants by Administering Nirsevimab to Infants, With or Without Maternal RSV Vaccination","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Annecy Genevois","startDate":"2026-01","conditions":"RSV Immunization","enrollment":1000},{"nctId":"NCT04955626","phase":"PHASE3","title":"To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2021-07-01","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":16372},{"nctId":"NCT05289037","phase":"PHASE2","title":"COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-03-30","conditions":"COVID-19","enrollment":1270},{"nctId":"NCT05556720","phase":"PHASE3","title":"Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Monash University","startDate":"2022-12-01","conditions":"HIV, Organ Transplantation, Lymphoma, Non-Hodgkin","enrollment":960},{"nctId":"NCT06647654","phase":"","title":"Impact and Effectiveness of ABRYSVO® Vaccination During Pregnancy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-08-26","conditions":"Respiratory Syncytial Virus, Respiratory Tract Diseases","enrollment":1},{"nctId":"NCT06556147","phase":"PHASE1","title":"A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vicebio Australia Proprietary Limited","startDate":"2024-08-13","conditions":"Healthy Volunteers","enrollment":144},{"nctId":"NCT05472038","phase":"PHASE2, PHASE3","title":"A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2022-07-26","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":1453},{"nctId":"NCT04429295","phase":"PHASE3","title":"Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-06-28","conditions":"Pertussis Immunisation, Diphtheria Immunisation, Polio Immunisation","enrollment":460},{"nctId":"NCT04762680","phase":"PHASE2, PHASE3","title":"Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-02-24","conditions":"COVID-19","enrollment":3159},{"nctId":"NCT05543616","phase":"PHASE2, PHASE3","title":"A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2022-09-23","conditions":"SARS-CoV-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19","enrollment":4292},{"nctId":"NCT02834637","phase":"PHASE3","title":"A Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls","status":"ACTIVE_NOT_RECRUITING","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2017-02-23","conditions":"Human Papilloma Virus","enrollment":930},{"nctId":"NCT07128121","phase":"PHASE2","title":"A Phase 2 Study to Describe the Safety and Immunogenicity of Respiratory Syncytial Virus Vaccine IN006 in Healthy Participants Aged 60 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shenzhen Shenxin Biotechnology Co., Ltd","startDate":"2025-08-13","conditions":"Respiratory Syncytial Virus (RSV) Infection","enrollment":500},{"nctId":"NCT03180034","phase":"PHASE4","title":"Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-11-29","conditions":"Human Papillomavirus Infection, Human Papillomavirus-Related Cervical Carcinoma","enrollment":27945},{"nctId":"NCT05000216","phase":"PHASE2","title":"COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-08-13","conditions":"Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris","enrollment":258},{"nctId":"NCT06984094","phase":"PHASE1","title":"First-in-human Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults","status":"RECRUITING","sponsor":"Clover Biopharmaceuticals AUS Pty","startDate":"2025-06-18","conditions":"Respiratory Syncytial Virus Vaccination, Human Metapneumovirus Vaccination, Parainfluenza Vaccination","enrollment":192},{"nctId":"NCT03728881","phase":"PHASE3","title":"Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the PRIMAVERA-ESCUDDO Trial","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-04-01","conditions":"Human Papillomavirus-Related Cervical Carcinoma","enrollment":1240},{"nctId":"NCT06113692","phase":"","title":"A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis After Moderna COVID-19 Vaccine","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-03-31","conditions":"Myocarditis, Pericarditis","enrollment":1169},{"nctId":"NCT06243666","phase":"","title":"Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xiamen University","startDate":"2024-02-20","conditions":"Cervical Intraepithelial Neoplasia, Cervical Cancer, Persistent Infection","enrollment":2188},{"nctId":"NCT04848584","phase":"","title":"Pfizer-BioNTech COVID-19 Vaccine Effectiveness Study - Kaiser Permanente Southern California","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-05-15","conditions":"COVID-19","enrollment":1},{"nctId":"NCT05596734","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2022-10-28","conditions":"Influenza, Human, COVID-19","enrollment":1019},{"nctId":"NCT05973006","phase":"PHASE3","title":"Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines","status":"COMPLETED","sponsor":"Novavax","startDate":"2023-08-16","conditions":"COVID-19","enrollment":400},{"nctId":"NCT07041190","phase":"PHASE3","title":"Pregnancy and Infant PrEparedness pLatform IN Europe, RSV-International Adaptive Platform Trial to Evaluate Two Approved Prevention Options to Prevent Respiratory Syncytial Virus in Infants: Maternal Vaccine to Women in Pregnancy and Monoclonal Antibody to the Infants, Given Alone or in Combination.","status":"NOT_YET_RECRUITING","sponsor":"PENTA Foundation","startDate":"2025-09","conditions":"RSV Immunization","enrollment":1500},{"nctId":"NCT07016152","phase":"PHASE1","title":"An Open-label, Dose-finding, Phase I Study to Evaluate the Safety and Immunogenicity of a Bivalent Klebsiella Pneumoniae Vaccine (CHO-V08) in Healthy Adults","status":"RECRUITING","sponsor":"Cho Pharma Inc.","startDate":"2025-06-26","conditions":"Klebsiella Pneumoniae Infection, Vaccine","enrollment":40},{"nctId":"NCT05518487","phase":"PHASE2","title":"COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-02-20","conditions":"COVID-19, Kidney Transplant","enrollment":15},{"nctId":"NCT05291845","phase":"PHASE2","title":"Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts","status":"RECRUITING","sponsor":"Zagazig University","startDate":"2022-04-03","conditions":"Warts, Human Papilloma Virus","enrollment":162},{"nctId":"NCT06743334","phase":"","title":"Secondary Databased Post-marketing Surveillance Study of BNT162b2","status":"COMPLETED","sponsor":"Pfizer","startDate":"2025-04-23","conditions":"COVID-19, SARS-CoV-2","enrollment":1},{"nctId":"NCT06194318","phase":"PHASE1","title":"First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy Adults","status":"COMPLETED","sponsor":"Clover Biopharmaceuticals AUS Pty","startDate":"2023-12-13","conditions":"Respiratory Syncytial Virus Vaccination","enrollment":160},{"nctId":"NCT00911560","phase":"PHASE1, PHASE2","title":"Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2009-05-27","conditions":"Neuroblastoma","enrollment":374},{"nctId":"NCT06137664","phase":"PHASE1, PHASE2","title":"Study of Trivalent and Bivalent (Types 1 & 2) Novel Oral Poliomyelitis Vaccines","status":"RECRUITING","sponsor":"PATH","startDate":"2024-11-20","conditions":"Poliomyelitis","enrollment":2400},{"nctId":"NCT05933304","phase":"","title":"A Study of the Effectiveness of Moderna COVID-19 Vaccine","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2020-12-18","conditions":"SARS-CoV-2, COVID-19","enrollment":927004},{"nctId":"NCT02935686","phase":"PHASE1, PHASE2","title":"A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2017-03-31","conditions":"Healthy","enrollment":155},{"nctId":"NCT06843317","phase":"PHASE1","title":"Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults","status":"RECRUITING","sponsor":"Clover Biopharmaceuticals USA, LLC","startDate":"2025-03-21","conditions":"RSV Infection","enrollment":160},{"nctId":"NCT06944717","phase":"PHASE1","title":"A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years Old","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vaxart","startDate":"2025-03-03","conditions":"Norovirus Infections","enrollment":60},{"nctId":"NCT06255626","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2024-05-27","conditions":"COVID-19","enrollment":215},{"nctId":"NCT05626803","phase":"PHASE2","title":"A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers","status":"COMPLETED","sponsor":"Vaxart","startDate":"2023-01-26","conditions":"Norovirus Infections","enrollment":135},{"nctId":"NCT05431933","phase":"PHASE3","title":"Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Schedule, and Protective Effect in the Schedule With Bivalent OPV in Infants","status":"COMPLETED","sponsor":"LG Chem","startDate":"2023-01-10","conditions":"Poliomyelitis, Vaccine Reaction","enrollment":2001},{"nctId":"NCT05079750","phase":"PHASE1","title":"A Study of a New Vaccine Against Two Types of Ebola","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2021-11-11","conditions":"Ebola","enrollment":26},{"nctId":"NCT04235257","phase":"PHASE4","title":"Intradermal, Fractional Dose of HPV Vaccines:","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2020-11-01","conditions":"HPV Infection, HPV Vaccine","enrollment":40},{"nctId":"NCT05291871","phase":"PHASE4","title":"Immunogenicity of Fractional Dose of the HPV Vaccines","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2022-06-15","conditions":"HPV Infection, HPV Vaccine","enrollment":92},{"nctId":"NCT06333704","phase":"","title":"Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT and SPIKEVAX X Injection.","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2023-03-10","conditions":"SARS-CoV-2","enrollment":4206},{"nctId":"NCT06007781","phase":"PHASE1","title":"Safety and Immunogenicity of HIL-214 in Healthy Japanese Infants","status":"COMPLETED","sponsor":"HilleVax","startDate":"2023-08-18","conditions":"Gastroenteritis","enrollment":21},{"nctId":"NCT06099613","phase":"PHASE1, PHASE2","title":"Study to Safety, Tolerability and Immunogenicity of EG-COVII in Healthy Adult","status":"COMPLETED","sponsor":"EyeGene Inc.","startDate":"2023-11-30","conditions":"COVID-19","enrollment":40},{"nctId":"NCT06838195","phase":"PHASE3","title":"Clinical Trial of the S. Flexneri-S. Sonnei Bivalent Conjugate Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2025-04-15","conditions":"Dysentery, Dysentery, Shigella","enrollment":8000},{"nctId":"NCT03307915","phase":"PHASE1","title":"A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2018-03-05","conditions":"Human Immunodeficiency Virus","enrollment":25},{"nctId":"NCT04508309","phase":"PHASE3","title":"Phase 3 Trial of a Bivalent Human Papilloma Virus (HPV) Vaccine (Cecolin®) in Young Girls","status":"COMPLETED","sponsor":"PATH","startDate":"2021-03-15","conditions":"Cervical Cancer","enrollment":1025},{"nctId":"NCT04066881","phase":"PHASE2","title":"A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP","status":"COMPLETED","sponsor":"MRC/UVRI and LSHTM Uganda Research Unit","startDate":"2020-12-15","conditions":"HIV Infections","enrollment":1512},{"nctId":"NCT06776055","phase":"","title":"Long-term Follow-up of Bivalent Human Papillomavirus (HPV) Vaccine Study in Women","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Zerun Biotechnology Co.,Ltd","startDate":"2023-03-27","conditions":"Cervical Cancer, Vulvar Cancer, Vaginal Cancer","enrollment":5372},{"nctId":"NCT06734832","phase":"PHASE3","title":"Efficacy, Safety, and Immunogenicity of the Bivalent Inactivated Enterovirus Vaccine (Vero Cell)","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2024-12-13","conditions":"Hand, Foot, and Mouth Disease（HFMD)","enrollment":8000},{"nctId":"NCT06666179","phase":"PHASE1","title":"Safety and Immunogenicity Study of SCB-1019T in Children","status":"WITHDRAWN","sponsor":"Clover Biopharmaceuticals AUS Pty","startDate":"2025-10","conditions":"RSV Infection","enrollment":""},{"nctId":"NCT06748612","phase":"PHASE4","title":"Immunogenicity of Different Primary Immunization Schedules with Inactivated Poliovirus Vaccine (IPV) Plus Pentavalent Vaccine (DTwP-HBV-Hib) or with Hexavalent Vaccine (DTwP-HBV-Hib-IPV)","status":"NOT_YET_RECRUITING","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2025-01-28","conditions":"Polio","enrollment":1190},{"nctId":"NCT06130345","phase":"","title":"Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-04-14","conditions":"SARS-CoV-2","enrollment":15196685},{"nctId":"NCT05886777","phase":"PHASE2","title":"A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-06-05","conditions":"Healthy Participants","enrollment":1142},{"nctId":"NCT05925127","phase":"PHASE2, PHASE3","title":"Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines","status":"COMPLETED","sponsor":"Novavax","startDate":"2023-10-16","conditions":"COVID-19","enrollment":994},{"nctId":"NCT05586204","phase":"NA","title":"Boost Intentions and Facilitate Action to Promote COVID-19 Booster Take-up","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2022-10-18","conditions":"COVID-19, Vaccines","enrollment":154977},{"nctId":"NCT05586178","phase":"NA","title":"Information Provision and Consistency Framing to Increase COVID-19 Booster Uptake","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2022-10-18","conditions":"COVID-19, Vaccines","enrollment":177720},{"nctId":"NCT05586165","phase":"NA","title":"Effects of Prompt to Bundle COVID-19 Booster and Flu Shot","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2022-10-18","conditions":"COVID-19, Vaccines","enrollment":109493},{"nctId":"NCT06287450","phase":"PHASE1","title":"A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adults","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen Shenxin Biotechnology Co., Ltd","startDate":"2025-08","conditions":"Respiratory Syncytial Virus Infections","enrollment":200},{"nctId":"NCT06441955","phase":"PHASE4","title":"Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.","status":"RECRUITING","sponsor":"Well- Konnect Healthcare Services and Research Firm","startDate":"2024-03-01","conditions":"COVID-19, Long Haul","enrollment":100},{"nctId":"NCT06645665","phase":"PHASE1","title":"A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adult Aged 18 Years and Above","status":"RECRUITING","sponsor":"Shenzhen Shenxin Biotechnology Co., Ltd","startDate":"2024-11-11","conditions":"Respiratory Syncytial Virus Infections","enrollment":240},{"nctId":"NCT05993325","phase":"PHASE3","title":"Immunogenicity and Safety of AdCLD-CoV19-1 OMI As a Booster: a COVID-19 Preventive Vaccine in Healthy Volunteers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cellid Co., Ltd.","startDate":"2023-11-27","conditions":"COVID-19, Vaccines","enrollment":4000},{"nctId":"NCT04904549","phase":"PHASE3","title":"Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-08-20","conditions":"COVID-19","enrollment":23726},{"nctId":"NCT04893811","phase":"PHASE4","title":"Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromised Participants ≥10 Years of Age","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-08-18","conditions":"Meningococcal Vaccine","enrollment":53},{"nctId":"NCT04579510","phase":"PHASE2","title":"Immunogenicity nOPV2 With and Without bOPV","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2021-02-08","conditions":"Poliomyelitis","enrollment":795},{"nctId":"NCT05858450","phase":"","title":"This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-05-05","conditions":"Influenza, Human, COVID-19","enrollment":3442996},{"nctId":"NCT03284710","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-06-19","conditions":"HIV Infections","enrollment":132},{"nctId":"NCT03460002","phase":"PHASE4","title":"Vaccine Campaign Effects on General Hospital Admissions and Mortality Among Children","status":"COMPLETED","sponsor":"Bandim Health Project","startDate":"2016-11","conditions":"Measles Vaccination, Oral Polio Vaccine, Non-specific/Heterologous Effects of Vaccines","enrollment":28612},{"nctId":"NCT03964415","phase":"PHASE3","title":"A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2019-10-31","conditions":"Healthy","enrollment":3900},{"nctId":"NCT05765578","phase":"","title":"An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5)","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-03-08","conditions":"COVID-19","enrollment":1713},{"nctId":"NCT05911048","phase":"PHASE2","title":"A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination","status":"NOT_YET_RECRUITING","sponsor":"WestVac Biopharma Co., Ltd.","startDate":"2024-12-30","conditions":"COVID-19","enrollment":3100},{"nctId":"NCT02968849","phase":"PHASE2, PHASE3","title":"Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-10-26","conditions":"HIV Infections","enrollment":5404},{"nctId":"NCT05372588","phase":"PHASE3","title":"Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines","status":"COMPLETED","sponsor":"Novavax","startDate":"2022-05-25","conditions":"COVID-19, SARS CoV 2 Infection","enrollment":1340},{"nctId":"NCT06345885","phase":"PHASE4","title":"Immunogenicity and Safety of One Dose of HPV Vaccine","status":"COMPLETED","sponsor":"Xiamen Innovax Biotech Co., Ltd","startDate":"2023-02-23","conditions":"Human Papillomavirus Vaccines","enrollment":200},{"nctId":"NCT05970887","phase":"PHASE4","title":"Immunogenicity and Safety of Concomitant Administration of Bivalent COVID-19 Vaccines With Influenza Vaccines","status":"COMPLETED","sponsor":"Catholic Kwandong University","startDate":"2022-10-12","conditions":"Immune Response, Safety","enrollment":154},{"nctId":"NCT04645966","phase":"PHASE2","title":"A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants","status":"TERMINATED","sponsor":"Pfizer","startDate":"2020-11-26","conditions":"Meningococcal Vaccine","enrollment":326}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CERVARIX"],"phase":"marketed","status":"active","brandName":"Bivalent Vaccines","genericName":"Bivalent Vaccines","companyName":"Instituto Nacional de Salud Publica, Mexico","companyId":"instituto-nacional-de-salud-publica-mexico","modality":"Biologic","firstApprovalDate":"","aiSummary":"Bivalent vaccines stimulate immune responses against two distinct pathogenic targets or variants simultaneously. Used for Influenza prevention (bivalent formulations), COVID-19 prevention (bivalent formulations against original and variant strains).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}